Advertisement

International Ophthalmology

, Volume 38, Issue 5, pp 1817–1823 | Cite as

Serum and aqueous humor concentrations of interleukin-27 in diabetic retinopathy patients

  • Maha E. Houssen
  • Mona Abo Bakr El-Hussiny
  • Amr El-Kannishy
  • Dalia Sabry
  • Rasha El Mahdy
  • Mohamed E. Shaker
Original Paper

Abstract

Purpose

Interleukin (IL)-27 has been reported to possess anti- and proinflammatory properties in several immune related-disorders, but its role in diabetic retinopathy is still elusive. Here, we aimed to (i) evaluate IL-27 concentrations in serum and aqueous humor of diabetic patients with or without retinopathy and (ii) test whether IL-27 is correlated with some risk factors of diabetic retinopathy.

Methods

The study comprised 60 diabetic patients with and without retinopathy along with 20 healthy controls. Serum and aqueous humor concentrations of IL-27 were assessed by ELISA.

Results

The mean of IL-27 concentration in aqueous humor in patients with diabetic retinopathy (6.7 ± 2.7 ng/L) was significantly elevated in comparison with either diabetic patients without retinopathy (4.6 ± 0.5 ng/L) or healthy control group (4.1 ± 0.8 ng/L). Besides, IL-27 concentration in aqueous humor was positively correlated with serum glucose, lipid profile and glycated hemoglobin (HbA1c).

Conclusions

Based on this study, IL-27 is implicated in the pathogenesis of diabetic retinopathy and positively correlates with the disorder progression.

Keywords

Diabetic retinopathy IL-27 Glycated hemoglobin Cholesterol Triglycerides 

Notes

Compliance with ethical standards

Conflict of interest

The authors report no conflicts of interest to disclose.

References

  1. 1.
    Cheung N, Mitchell P, Wong TY (2010) Diabetic retinopathy. Lancet 376(9735):124–136CrossRefPubMedCentralGoogle Scholar
  2. 2.
    Adamis A (2002) Is diabetic retinopathy an inflammatory disease? Br J Ophthalmol 86(4):363–365CrossRefPubMedCentralGoogle Scholar
  3. 3.
    Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414(6865):813–820CrossRefPubMedCentralGoogle Scholar
  4. 4.
    Goldberg RB (2009) Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. J Clin Endocrinol Metab 94(9):3171–3182CrossRefPubMedCentralGoogle Scholar
  5. 5.
    dell’Omo R, Semeraro F, Bamonte G, Cifariello F, Romano MR, Costagliola C (2013) Vitreous mediators in retinal hypoxic diseases. Mediat Inflamm 2013:935301Google Scholar
  6. 6.
    Noda K, Nakao S, Ishida S, Ishibashi T (2012) Leukocyte adhesion molecules in diabetic retinopathy. J Ophthalmol 2012:279037CrossRefPubMedCentralGoogle Scholar
  7. 7.
    Yoshida H, Nakaya M, Miyazaki Y (2009) Interleukin 27: a double-edged sword for offense and defense. J Leukoc Biol 86(6):1295–1303CrossRefPubMedCentralGoogle Scholar
  8. 8.
    Kastelein RA, Hunter CA, Cua DJ (2007) Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. Annu Rev Immunol 25:221–242CrossRefPubMedCentralGoogle Scholar
  9. 9.
    Pflanz S, Timans JC, Cheung J, Rosales R, Kanzler H, Gilbert J, Hibbert L, Churakova T, Travis M, Vaisberg E (2002) IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T cells. Immunity 16(6):779–790CrossRefGoogle Scholar
  10. 10.
    Hunter CA, Kastelein R (2012) Interleukin-27: balancing protective and pathological immunity. Immunity 37(6):960–969CrossRefPubMedCentralGoogle Scholar
  11. 11.
    Liu H, Rohowsky-Kochan C (2011) Interleukin-27-mediated suppression of human Th17 cells is associated with activation of STAT1 and suppressor of cytokine signaling protein 1. J Interferon Cytokine Res 31(5):459–469CrossRefPubMedCentralGoogle Scholar
  12. 12.
    Bucolo G, David H (1973) Quantitative determination of serum triglycerides by use of enzymes. Clin Chem 19(5): 476–482PubMedPubMedCentralGoogle Scholar
  13. 13.
    Meiattini F, Prencipe L, Bardelli F, Giannini G, Tarli P (1978) The 4-hydroxybenzoate/4-aminophenazone chromogenic system. Clin Chem 24(12): 2161–2165PubMedPubMedCentralGoogle Scholar
  14. 14.
    Burtis CA, Ashwood ER, Bruns DE (1999) Tietz. In: Texbook of Clinical Chemistry, 3rd edn. WB Saunders, Philadelphia, PAGoogle Scholar
  15. 15.
    Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18(6):499–502PubMedPubMedCentralGoogle Scholar
  16. 16.
    Trinder P (1969) Determination of blood glucose using an oxidase-peroxidase system with a non-carcinogenic chromogen. J Clin Pathol 22(2):158–161CrossRefPubMedCentralGoogle Scholar
  17. 17.
    Trivelli LA, Ranney HM, Lai H-T (1971) Hemoglobin components in patients with diabetes mellitus. N Engl J Med 284(7):353–357CrossRefPubMedCentralGoogle Scholar
  18. 18.
    Lee YS, Amadi-Obi A, Yu CR, Egwuagu CE (2011) Retinal cells suppress intraocular inflammation (uveitis) through production of interleukin-27 and interleukin-10. Immunology 132(4):492–502CrossRefPubMedCentralGoogle Scholar
  19. 19.
    Awasthi A, Carrier Y, Peron JP, Bettelli E, Kamanaka M, Flavell RA, Kuchroo VK, Oukka M, Weiner HL (2007) A dominant function for interleukin 27 in generating interleukin 10–producing anti-inflammatory T cells. Nat Immunol 8(12):1380–1389CrossRefPubMedCentralGoogle Scholar
  20. 20.
    Liu X, Mameza MG, Lee YS, Eseonu CI, Yu C-R, Derwent JJK, Egwuagu CE (2008) Suppressors of cytokine-signaling proteins induce insulin resistance in the retina and promote survival of retinal cells. Diabetes 57(6):1651–1658CrossRefPubMedCentralGoogle Scholar
  21. 21.
    Villarino AV, Stumhofer JS, Saris CJ, Kastelein RA, de Sauvage FJ, Hunter CA (2006) IL-27 limits IL-2 production during Th1 differentiation. J Immunol 176(1):237–247CrossRefPubMedCentralGoogle Scholar
  22. 22.
    Diveu C, McGeachy MJ, Boniface K, Stumhofer JS, Sathe M, Joyce-Shaikh B, Chen Y, Tato CM, McClanahan TK, de Waal Malefyt R (2009) IL-27 blocks RORc expression to inhibit lineage commitment of Th17 cells. J Immunol 182(9):5748–5756CrossRefPubMedCentralGoogle Scholar
  23. 23.
    Hirahara K, Ghoreschi K, Yang X-P, Takahashi H, Laurence A, Vahedi G, Sciumè G, Hall AOH, Dupont CD, Francisco LM (2012) Interleukin-27 priming of T cells controls IL-17 production in trans via induction of the ligand PD-L1. Immunity 36(6):1017–1030CrossRefPubMedCentralGoogle Scholar
  24. 24.
    Antunica AG, Karaman K, Znaor L, Sapunar A, Buško V, Puzović V (2012) IL-12 concentrations in the aqueous humor and serum of diabetic retinopathy patients. Graefes Arch Clin Exp Ophthalmol 250(6):815–821CrossRefGoogle Scholar
  25. 25.
    Zorena K, Mysliwska J, Mysliwiec M, Balcerska A, Lipowski P, Raczynska K (2008) Interleukin-12 and tumour necrosis factor-alpha equilibrium is a prerequisite for clinical course free from late complications in children with type 1 diabetes mellitus. Scand J Immunol 67(2):204–208CrossRefPubMedCentralGoogle Scholar
  26. 26.
    Takeda A, Hamano S, Yamanaka A, Hanada T, Ishibashi T, Mak TW, Yoshimura A, Yoshida H (2003) Cutting edge: role of IL-27/WSX-1 signaling for induction of T-bet through activation of STAT1 during initial Th1 commitment. J Immunol 170(10):4886–4890CrossRefPubMedCentralGoogle Scholar
  27. 27.
    Owaki T, Asakawa M, Fukai F, Mizuguchi J, Yoshimoto T (2006) IL-27 induces Th1 differentiation via p38 MAPK/T-bet-and intercellular adhesion molecule-1/LFA-1/ERK1/2-dependent pathways. J Immunol 177(11):7579–7587CrossRefPubMedCentralGoogle Scholar
  28. 28.
    Schram MT, Chaturvedi N, Schalkwijk C, Giorgino F, Ebeling P, Fuller JH, Stehouwer CD (2003) Vascular risk factors and markers of endothelial function as determinants of inflammatory markers in type 1 diabetes. Diabetes Care 26(7):2165–2173CrossRefPubMedCentralGoogle Scholar
  29. 29.
    Winkler G, Dworak O, Salamon F, Salamon D, Speer G, Cseh K (1998) Increased interleukin-12 plasma concentrations in both, insulin-dependent and non-insulin-dependent diabetes mellitus. Diabetologia 41(4):488–488CrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2017

Authors and Affiliations

  • Maha E. Houssen
    • 1
  • Mona Abo Bakr El-Hussiny
    • 2
  • Amr El-Kannishy
    • 3
  • Dalia Sabry
    • 3
  • Rasha El Mahdy
    • 4
  • Mohamed E. Shaker
    • 5
  1. 1.Department of Biochemistry, Faculty of PharmacyDamanhour UniversityDamanhourEgypt
  2. 2.Department of Clinical Pathology, Faculty of MedicineMansoura UniversityMansouraEgypt
  3. 3.Department of Ophthalmology, Faculty of MedicineMansoura UniversityMansouraEgypt
  4. 4.Department of Medical Microbiology and Immunology, Faculty of MedicineMansoura UniversityMansouraEgypt
  5. 5.Department of Pharmacology and Toxicology, Faculty of PharmacyMansoura UniversityMansouraEgypt

Personalised recommendations